Quality of Life in Men With Locally Advanced Adenocarcinoma of the Prostate

An Exploratory Analysis Using Data From the CaPSURE Database

Wesley White, Natalia Sadetsky, W Waters, Peter R. Carroll, Mark S. Litwin

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Purpose: We present longitudinal quality of life outcomes in a national observational cohort of men with locally advanced prostate adenocarcinoma. Materials and Methods: The CaPSURE® registry was used to evaluate quality of life in men with clinical T3 or T4 prostate adenocarcinoma who underwent primary treatment and had a minimum followup of 2 years. Records were reviewed for treatment, patient age, T stage, prostate specific antigen at diagnosis, body mass index, and initial and posttreatment quality of life using the SF-36® and UCLA-PCI questionnaires, which can each be scored from 0 to 100 with higher scores indicating better outcomes. The association of treatment type and quality of life changes after treatment were evaluated with multivariate mixed model analysis, adjusting for age, time of quality of life assessment, and interaction between treatment and time. Results: Of the 13,740 men enrolled in CaPSURE 608 (4.42%) presented with T3 or T4 tumors. In this subgroup 151 men completed baseline and a minimum of 2 years of followup with quality of life data available. These men underwent primary treatment with radical prostatectomy (21%), cryotherapy (8%), brachytherapy (17%) or hormonal ablation (54%). The treatment cohort demonstrated significant decreases in quality of life, most profoundly in urinary and sexual function. Mean urinary function was 91 at baseline, which decreased to 82, 83 and 82 at 1, 2 and 3 years after treatment, respectively (p = 0.04). Mean sexual function was 38 at baseline, which decreased to 15, 16 and 14 at 1, 2 and 3 years after treatment, respectively (p <0.01). On multivariate analysis quality of life varied significantly by treatment type (p <0.01). Conclusions: Treatment for locally advanced prostate adenocarcinoma is associated with a significant burden in patients, notably decrements in urinary and sexual function. Clinicians should consider the impact that treatment imparts on quality of life when counseling patients with locally advanced disease.

Original languageEnglish (US)
Pages (from-to)2409-2414
Number of pages6
JournalJournal of Urology
Volume180
Issue number6
DOIs
StatePublished - Dec 1 2008
Externally publishedYes

Fingerprint

Prostate
Adenocarcinoma
Quality of Life
Databases
Therapeutics
Cryotherapy
Brachytherapy
Prostate-Specific Antigen
Prostatectomy
Registries
Counseling
Body Mass Index
Multivariate Analysis

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

Quality of Life in Men With Locally Advanced Adenocarcinoma of the Prostate : An Exploratory Analysis Using Data From the CaPSURE Database. / White, Wesley; Sadetsky, Natalia; Waters, W; Carroll, Peter R.; Litwin, Mark S.

In: Journal of Urology, Vol. 180, No. 6, 01.12.2008, p. 2409-2414.

Research output: Contribution to journalArticle

@article{6e58919dc50244439fa78355a98554c6,
title = "Quality of Life in Men With Locally Advanced Adenocarcinoma of the Prostate: An Exploratory Analysis Using Data From the CaPSURE Database",
abstract = "Purpose: We present longitudinal quality of life outcomes in a national observational cohort of men with locally advanced prostate adenocarcinoma. Materials and Methods: The CaPSURE{\circledR} registry was used to evaluate quality of life in men with clinical T3 or T4 prostate adenocarcinoma who underwent primary treatment and had a minimum followup of 2 years. Records were reviewed for treatment, patient age, T stage, prostate specific antigen at diagnosis, body mass index, and initial and posttreatment quality of life using the SF-36{\circledR} and UCLA-PCI questionnaires, which can each be scored from 0 to 100 with higher scores indicating better outcomes. The association of treatment type and quality of life changes after treatment were evaluated with multivariate mixed model analysis, adjusting for age, time of quality of life assessment, and interaction between treatment and time. Results: Of the 13,740 men enrolled in CaPSURE 608 (4.42{\%}) presented with T3 or T4 tumors. In this subgroup 151 men completed baseline and a minimum of 2 years of followup with quality of life data available. These men underwent primary treatment with radical prostatectomy (21{\%}), cryotherapy (8{\%}), brachytherapy (17{\%}) or hormonal ablation (54{\%}). The treatment cohort demonstrated significant decreases in quality of life, most profoundly in urinary and sexual function. Mean urinary function was 91 at baseline, which decreased to 82, 83 and 82 at 1, 2 and 3 years after treatment, respectively (p = 0.04). Mean sexual function was 38 at baseline, which decreased to 15, 16 and 14 at 1, 2 and 3 years after treatment, respectively (p <0.01). On multivariate analysis quality of life varied significantly by treatment type (p <0.01). Conclusions: Treatment for locally advanced prostate adenocarcinoma is associated with a significant burden in patients, notably decrements in urinary and sexual function. Clinicians should consider the impact that treatment imparts on quality of life when counseling patients with locally advanced disease.",
author = "Wesley White and Natalia Sadetsky and W Waters and Carroll, {Peter R.} and Litwin, {Mark S.}",
year = "2008",
month = "12",
day = "1",
doi = "10.1016/j.juro.2008.08.079",
language = "English (US)",
volume = "180",
pages = "2409--2414",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Quality of Life in Men With Locally Advanced Adenocarcinoma of the Prostate

T2 - An Exploratory Analysis Using Data From the CaPSURE Database

AU - White, Wesley

AU - Sadetsky, Natalia

AU - Waters, W

AU - Carroll, Peter R.

AU - Litwin, Mark S.

PY - 2008/12/1

Y1 - 2008/12/1

N2 - Purpose: We present longitudinal quality of life outcomes in a national observational cohort of men with locally advanced prostate adenocarcinoma. Materials and Methods: The CaPSURE® registry was used to evaluate quality of life in men with clinical T3 or T4 prostate adenocarcinoma who underwent primary treatment and had a minimum followup of 2 years. Records were reviewed for treatment, patient age, T stage, prostate specific antigen at diagnosis, body mass index, and initial and posttreatment quality of life using the SF-36® and UCLA-PCI questionnaires, which can each be scored from 0 to 100 with higher scores indicating better outcomes. The association of treatment type and quality of life changes after treatment were evaluated with multivariate mixed model analysis, adjusting for age, time of quality of life assessment, and interaction between treatment and time. Results: Of the 13,740 men enrolled in CaPSURE 608 (4.42%) presented with T3 or T4 tumors. In this subgroup 151 men completed baseline and a minimum of 2 years of followup with quality of life data available. These men underwent primary treatment with radical prostatectomy (21%), cryotherapy (8%), brachytherapy (17%) or hormonal ablation (54%). The treatment cohort demonstrated significant decreases in quality of life, most profoundly in urinary and sexual function. Mean urinary function was 91 at baseline, which decreased to 82, 83 and 82 at 1, 2 and 3 years after treatment, respectively (p = 0.04). Mean sexual function was 38 at baseline, which decreased to 15, 16 and 14 at 1, 2 and 3 years after treatment, respectively (p <0.01). On multivariate analysis quality of life varied significantly by treatment type (p <0.01). Conclusions: Treatment for locally advanced prostate adenocarcinoma is associated with a significant burden in patients, notably decrements in urinary and sexual function. Clinicians should consider the impact that treatment imparts on quality of life when counseling patients with locally advanced disease.

AB - Purpose: We present longitudinal quality of life outcomes in a national observational cohort of men with locally advanced prostate adenocarcinoma. Materials and Methods: The CaPSURE® registry was used to evaluate quality of life in men with clinical T3 or T4 prostate adenocarcinoma who underwent primary treatment and had a minimum followup of 2 years. Records were reviewed for treatment, patient age, T stage, prostate specific antigen at diagnosis, body mass index, and initial and posttreatment quality of life using the SF-36® and UCLA-PCI questionnaires, which can each be scored from 0 to 100 with higher scores indicating better outcomes. The association of treatment type and quality of life changes after treatment were evaluated with multivariate mixed model analysis, adjusting for age, time of quality of life assessment, and interaction between treatment and time. Results: Of the 13,740 men enrolled in CaPSURE 608 (4.42%) presented with T3 or T4 tumors. In this subgroup 151 men completed baseline and a minimum of 2 years of followup with quality of life data available. These men underwent primary treatment with radical prostatectomy (21%), cryotherapy (8%), brachytherapy (17%) or hormonal ablation (54%). The treatment cohort demonstrated significant decreases in quality of life, most profoundly in urinary and sexual function. Mean urinary function was 91 at baseline, which decreased to 82, 83 and 82 at 1, 2 and 3 years after treatment, respectively (p = 0.04). Mean sexual function was 38 at baseline, which decreased to 15, 16 and 14 at 1, 2 and 3 years after treatment, respectively (p <0.01). On multivariate analysis quality of life varied significantly by treatment type (p <0.01). Conclusions: Treatment for locally advanced prostate adenocarcinoma is associated with a significant burden in patients, notably decrements in urinary and sexual function. Clinicians should consider the impact that treatment imparts on quality of life when counseling patients with locally advanced disease.

UR - http://www.scopus.com/inward/record.url?scp=55549091371&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55549091371&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2008.08.079

DO - 10.1016/j.juro.2008.08.079

M3 - Article

VL - 180

SP - 2409

EP - 2414

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 6

ER -